Quadruple immunotherapy for treating relapsed neuroblastoma in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and efficacy of a quadruple immunotherapy approach for pediatric patients with relapsed or refractory neuroblastoma. Participants will receive a combination of natural killer (NK) cells, anti-GD2 antibodies, cytokines (IL-2 and GM-CSF), and a retinoid X receptor gamma agonist, spironolactone. The treatment regimen includes intravenous and subcutaneous infusions over a specified timeline to enhance the immune response against the cancer. The study aims to determine if this innovative combination can improve outcomes for children facing this challenging condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* relapsed or refractory neuroblastoma
* Adequate organ function: creatinine clearance ≥40 ml/min/1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU/L, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air
* Karnofsky or Lansky performance status score ≥50
* Has an appropriate HLA-haploidentical NK-cell donor available

Exclusion Criteria:

* Pregnant or lactating woman
* HIV infection
* Patients for whom conventional treatment is deemed more appropriate
* Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy \<1 month

Where it's running

• Hong Kong Children's Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Daniel Cheuk — Hong Kong Children's Hospital
• Study coordinator: Daniel Cheuk
• Email: cheukkld@gmail.com
• Phone: 852-35136049

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding N-803 to chemoimmunotherapy for relapsed or refractory neuroblastoma

  This study tests whether adding the immune stimulant N-803 to a chemoimmunotherapy regimen helps children and young adults with relapsed or refractory neuroblastoma.

  Recruiting at 2 sites Phase 2 St. Jude Children's Research Hospital · San Francisco, California and 4 other locations · NCT07085338

• Prolonged Naxitamab with irinotecan, temozolomide, and sargramostim for relapsed or refractory neuroblastoma

  This trial will test whether giving the immunotherapy Naxitamab more slowly, along with irinotecan, temozolomide, and sargramostim, reduces infusion side effects for people with relapsed or refractory neuroblastoma.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07027748

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• 177Lu-DOTATATE treatment for children with high-risk neuroblastoma

  This study is testing a new treatment called 177Lu-DOTATATE to see if it can help children with high-risk neuroblastoma that has come back or worsened.

  Recruiting at 9 sites Phase 2 Karolinska University Hospital · Copenhagen, Copenhagen and 8 other locations · NCT04903899

• Using engineered T-cells to treat relapsed or refractory neuroblastoma in children

  This study is testing a new type of engineered T-cell treatment for children with relapsed or hard-to-treat neuroblastoma to see if it can help fight their cancer.

  Recruiting at 2 sites Phase 1 Nanjing Children's Hospital · Nanjing, Jiangsu and 1 other locations · NCT06751134

• Using NK cells to treat high-risk neuroblastoma in children

  This study is testing if injections of special immune cells can help children aged 2 to 16 with tough-to-treat neuroblastoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Kian Immune Cell Company · Tehran · NCT06674265

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.